Scientists / Our Scientists

Anwesha Dey

Principal Scientist, Discovery Oncology

Postdoc Mentor

"Genentech offers the incredible opportunity to pursue curiosity-driven intellectual inquiry and touch the lives of patients."

Years at Genentech

Publications

Awards & Honors

The focus of my lab is to gain new insights into signaling pathways in cancer biology. We are interested in identifying and validating new targets to contribute to the oncology drug discovery efforts. Working at Genentech offers the unique opportunity to focus on both cutting edge basic biology and translating our basic science discoveries for therapeutic intervention to potentially help patients.

Postdoctoral Mentor
I know first hand how enriching and rewarding the postdoc program at Genentech is. Joining Genentech as a postdoctoral fellow in Vishva Dixit’s lab was one of the best career decisions I ever took. The postdoc program at Genentech offers the opportunity to immerse oneself in the best science possible and collaborate with excellent scientists across multiple disciplines. Postdoc projects advance basic science, which often lays the foundation for key therapeutic discoveries. I feel very fortunate to have the opportunity to be a postdoc mentor.

Featured Publication

NeuCode Proteomics Reveals Bap1 Regulation of Metabolism.

Cell Rep. 2016 Jun 30. pii: S2211-1247(16)30738-0. doi: 10.1016/j.celrep.2016.05.096. [Epub ahead of print]

Baughman JM, Rose CM, Kolumam G, Webster JD, Wilkerson EM, Merrill AE, Rhoads TW, Noubade R, Katavolos P, Lesch J, Stapleton DS, Rabaglia ME, Schueler KL, Asuncion R, Domeyer M, Zavala-Solorio J, Reich M, DeVoss J, Keller MP, Attie AD, Hebert AS, Westphall MS, Coon JJ, Kirkpatrick DS, Dey A.

View Abstract

Loss of the tumor suppressor BAP1 causes myeloid transformation.

Science 2012, Aug. 9.

Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, Saunders LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM.

View Abstract

My lab currently has two focus areas: (a) Understanding the basic biology of the hippo signaling pathway and how it is deregulated in various cancers; and (b) investigating the tumor suppressor BAP1 and uncovering its roles in cancer, metabolism and development. Broadly, my lab uses a variety of biochemical and proteomics tools, cellular and mouse models to investigate how signaling pathways are deregulated in cancers.

Machine-learning and chemicogenomics approach defines and predicts cross-talk of hippo and MAPK pathways

Cancer Discovery, ISSN: 21598290 21598274

Trang Pham; Thijs Hagenbeek; Ho-June Lee; Jason Li; Christopher M. Rose; Eva Lin; Mamie Yu; Scott E. Martin; Robert Piskol; Jennifer A. Lacap; Deepak Sampath; Victoria Pham; Zora Modrusan; Jennie R. Lill; Christiaan N. Klijn; Shiva Malek; Matthew T. Chang; Anwesha Dey

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Anwesha Dey

Principal Scientist, Discovery Oncology

Featured Publication

NeuCode Proteomics Reveals Bap1 Regulation of Metabolism.

Loss of the tumor suppressor BAP1 causes myeloid transformation.